UK markets closed
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,069.73
    -619.17 (-2.73%)
     
  • CRUDE OIL

    77.94
    -1.74 (-2.18%)
     
  • GOLD FUTURES

    1,937.60
    -8.00 (-0.41%)
     
  • DOW

    33,807.76
    -170.32 (-0.50%)
     
  • BTC-GBP

    18,513.92
    -818.57 (-4.23%)
     
  • CMC Crypto 200

    515.97
    -21.90 (-4.07%)
     
  • ^IXIC

    11,433.75
    -187.96 (-1.62%)
     
  • ^FTAS

    4,265.16
    +6.19 (+0.15%)
     

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector

Company Logo
Company Logo

Global Adalimumab, Infliximab And Etanercept Biosimilars Market

Global Adalimumab, Infliximab And Etanercept Biosimilars Market
Global Adalimumab, Infliximab And Etanercept Biosimilars Market

Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.

The global adalimumab, infliximab and etanercept biosimilars market reached a value of nearly $2,757.45 million in 2021, having grown at a compound annual growth rate (CAGR) of 93.90% since 2016. The market is expected to grow from $2,757.45 million in 2021 to $5,591.82 million in 2026 at a rate of 15.20%. The market is then expected to grow at a CAGR of 9.96% from 2026 and reach $8,991.32 million in 2031.

Growth in the historic period resulted from increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs. The market was restrained by the companies gaining market share without a simple price war, low healthcare access and a lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, a rise in healthcare expenditure, aging population and an increase in healthcare access will drive market growth. Factors that could hinder the growth of the adalimumab, infliximab and etanercept biosimilars market in the future include insufficient and outdated health system infrastructure.

The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab. The adalimumab biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021. Going forward, the Cipleumab segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by product, at a CAGR of 17.18% during 2021-2026.

The adalimumab, infliximab and etanercept biosimilars market is also segmented by application into Crohn's disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and other applications. The other applications market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by application, accounting for 20.1% of the total in 2021. Going forward, the other applications segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by application, at a CAGR of 15.8% during 2021-2026.

The adalimumab, infliximab and etanercept biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, accounting for 87.7% of the total in 2021. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, at a CAGR of 32.2% during 2021-2026.

The global adalimumab, infliximab and etanercept biosimilars market is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 98.57% of the total market in 2021. Biogen was the largest competitor with 30.14% of the market, followed by Sandoz (Novartis) with23.83 %, Pfizer with 18.04%, Amgen with 7.67%, Celltrion with 4.26%, Samsung Bioepis (Samsung Biologics) with 4.07%, Hetero Drugs Limited with 3.08%, Fresenius Kabi AG with 2.75%, Boehringer Ingelheim with 2.54% and Biocon with2.19 %.

The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by application will arise in the other applications market segment, which will gain $ 601.4 of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel will arise in the hospital pharmacies market segment, which will gain $1,939.2 of global annual sales by 2026. The adalimumab, infliximab and etanercept biosimilars market size will gain the most in the USA at $738.0 million.

Market-trend-based strategies for the adalimumab, infliximab and etanercept biosimilars market include focus on launching new products, focus on mergers and acquisitions, focus on establishing strategic partnerships and focus on increasing investments.

Player-adopted strategies in the adalimumab, infliximab and etanercept biosimilars market include focus on expanding market presence through strategic collaborations and partnerships, focus on meeting the changing needs of health care providers and patients through launching new biosimilar formulations and focus on strengthening business operations through the launch of new products.

Report Attribute

Details

No. of Pages

252

Forecast Period

2021 - 2031

Estimated Market Value (USD) in 2021

$2757.45 Million

Forecasted Market Value (USD) by 2031

$8991.32 Million

Compound Annual Growth Rate

12.5%

Regions Covered

Global

Scope
Markets Covered:

  • 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab

  • 2) By Application: Crohn's Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications

  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Key Topics Covered:

1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics

7. Major Market Trends
7.1. Robust Competition in the Marketplace
7.2. Growing Mergers And Acquisitions
7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development
7.4. Large Number Of Strategic Partnerships
7.5. Increasing Investments In Biosimilars Market

8. Global Market Size And Growth

9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis

10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

11. Asia-Pacific Market

12. Western Europe Market

13. Eastern Europe Market

14. North America Market

15. South America Market

16. Middle East Market

17. Africa Market

18. Competitive Landscape And Company Profiles

19. Company Profiles

20. Pipeline Analysis

21. Key Mergers And Acquisitions In The Market

22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies

23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations

24. Appendix

Companies Mentioned

  • Biogen

  • Novartis (Sandoz)

  • Pfizer

  • Amgen

  • Celltrion

For more information about this report visit https://www.researchandmarkets.com/r/skkfsw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900